Targeting specific receptors in neuroblastoma treatment
NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma Management
This study is testing a new way to treat neuroblastoma in young children by using a special compound that helps deliver cancer-fighting medicine directly to the tumor, with the hope of making existing treatments work better and improving survival for kids with high-risk cases.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanopharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Rensselaer, United States) |
| Project ID | NIH-11004741 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for neuroblastoma, a common cancer in young children. The approach involves creating a dual-targeting ligand that can effectively bind to specific receptors on cancer cells, enhancing the delivery of therapeutic agents. By targeting the integrin αvβ3 and norepinephrine transporter, the treatment aims to improve the effectiveness of existing therapies and potentially increase survival rates for high-risk patients. The research utilizes advanced nanotechnology to create a compound that can deliver anticancer actions directly to the tumor.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under the age of 5 who have been diagnosed with high-risk neuroblastoma.
Not a fit: Patients with low-risk neuroblastoma or those older than 5 years may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for children with high-risk neuroblastoma.
How similar studies have performed: While the approach of dual targeting in cancer treatment is promising, this specific application in neuroblastoma is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Rensselaer, United States
- Nanopharmaceuticals, LLC — Rensselaer, United States (Active)
Researchers
- Principal investigator: Davis, Paul — Nanopharmaceuticals, LLC
- Study coordinator: Davis, Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.